NADAC acquisition cost data for TERIPARATIDE 620 MCG/2.48 ML. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 47781065289 | $996.60 | 2022-11-23 | Rx |
| 47781065289 | $996.60 | 2022-11-23 | Rx |
| 47781065289 | $996.60 | 2022-11-23 | Rx |
| 47781065289 | $996.60 | 2022-11-23 | Rx |
| 47781065289 | $996.60 | 2022-11-23 | Rx |
| 47781065289 | $996.60 | 2022-11-23 | Rx |
Generic: Teriparatide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | $956.6K | 334 | 138 | $1,017.71 |
| 2021 | $24.6M | 8,478 | 2,408 | $1,022.90 |
| 2022 | $62.4M | 21,705 | 3,949 | $1,031.25 |
| 2023 | $89.1M | 30,242 | 7,021 | $1,068.13 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $12.3M | 4,200 | 976 |
| New York | $8.7M | 2,893 | 655 |
| Texas | $6.4M | 2,115 | 558 |
| Pennsylvania | $5.4M | 2,019 | 432 |
| Ohio | $4.9M | 1,691 | 342 |
| Florida | $3.7M | 1,237 | 313 |
| Minnesota | $3.5M | 1,224 | 227 |
| Wisconsin | $2.7M | 996 | 194 |
| Illinois | $2.7M | 899 | 221 |
| Massachusetts | $2.7M | 897 | 262 |
| New Jersey | $2.4M | 749 | 195 |
| Michigan | $2.0M | 691 | 199 |
| South Carolina | $1.9M | 604 | 137 |
| Missouri | $1.9M | 639 | 150 |
| Colorado | $1.8M | 629 | 145 |
| Connecticut | $1.7M | 495 | 143 |
| North Carolina | $1.6M | 529 | 135 |
| Virginia | $1.5M | 515 | 119 |
| Georgia | $1.5M | 493 | 141 |
| Indiana | $1.5M | 531 | 152 |
| Washington | $1.5M | 509 | 107 |
| Maryland | $1.4M | 405 | 98 |
| Tennessee | $1.4M | 443 | 94 |
| Arizona | $1.4M | 412 | 107 |
| Kentucky | $1.3M | 449 | 109 |
| Vermont | $983.6K | 346 | 54 |
| Iowa | $891.9K | 333 | 61 |
| Oregon | $860.7K | 305 | 75 |
| Utah | $796.4K | 266 | 62 |
| New Hampshire | $790.3K | 252 | 63 |
| Louisiana | $770.0K | 295 | 65 |
| New Mexico | $721.3K | 227 | 50 |
| Oklahoma | $607.2K | 205 | 54 |
| Delaware | $577.8K | 182 | 36 |
| Kansas | $509.4K | 156 | 37 |
| North Dakota | $408.2K | 138 | 26 |
| West Virginia | $388.8K | 142 | 26 |
| Idaho | $373.9K | 136 | 42 |
| Maine | $369.1K | 134 | 30 |
| Nevada | $334.5K | 97 | 24 |
| Alabama | $319.6K | 114 | 42 |
| Arkansas | $276.5K | 86 | 20 |
| South Dakota | $254.1K | 98 | 16 |
| Montana | $235.4K | 74 | 20 |
| Puerto Rico | $214.2K | 84 | 19 |
| Hawaii | $205.3K | 69 | 21 |
| Alaska | $202.4K | 62 | 20 |
| Mississippi | $180.9K | 59 | 17 |
| Nebraska | $179.5K | 65 | 14 |
| Rhode Island | $82.9K | 30 | N/A |
| District of Columbia | $48.4K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.